Hypoglycemia Clinical Trial
Official title:
A Randomized, Three-way, Cross-over Study to Assess the Impact of Nocturnal Hypoglycemia on Sleep in Patients With Type 1 Diabetes
Growing evidence provided by many observational studies has established a strong link between
decreased sleep duration and poor glucoregulation. Sleep deprivation and poor sleep quality
induce insulin resistance and decrease glucose tolerance in healthy individuals. However, the
influence of poor sleep quality on glycemic control of patients with Type 1 diabetes mellitus
(T1DM) is unknown. Persistent sleep deprivation among patients with T1DM has been reported,
and this sleep loss can be attributed in part to nocturnal hypoglycemia. Nocturnal iatrogenic
hypoglycemia is a limitation of current intensive insulin therapies. Although severe
hypoglycemia is associated with adverse events such as seizures and death, less severe
nocturnal hypoglycemia has been linked to broad range of adverse consequences, both acutely
and long term. Hypoglycemia stimulates the sympathetic nervous system as a stress response,
leading to the stimulation of the hypothalamic-pituitary-adrenal axis (HPA). This results in
a counter regulatory hormone cascade, which elicits an excessive cortisol secretion, which is
known to cause sleep disturbance and could impair glucose homeostasis after the hypoglycemic
event. The hyperinsulinemia in T1DM patients promotes HPA hyperactivity as well, which is
also associated with impaired sleep quality by leading to sleep fragmentation, decreased slow
wave sleep and shortened sleep duration. Sleep disturbances due to nocturnal hypoglycemia can
exacerbate HPA axis dysfunction, adversely affecting the sleep-wake cycle.
The goal of the study is to understand the impact of nocturnal hypoglycemia on sleep.
The study duration is 4 weeks long, during which subjects will undergo a 1 week run-in period
followed by 3 randomized weeks of observational study. During the 1 week run-in period,
subjects will familiarize themselves with the CGM and the other data collection procedures.
Following the run-in week, the subject will be randomized to a specific order of observation
weeks. The three observation weeks are a resistance training week, an aerobic exercise week
and a control week with no explicit exercise. During the observation weeks, there will be 4
interventions planned, two during both the aerobic exercise and the resistance training week.
See Schematic below for details. During both the aerobic exercise week intervention visits,
subjects will exercise for ~45 minutes on a treadmill and during the resistance training
week, subjects will perform strength training exercises for 1-3 sets per exercise at a weight
that can be lifted for 8-12 repetitions (~60-80% of 1-repetition max). The duration of the
resistance training period is expected to be ~45min. Subjects will continue to perform daily
activities during each of the weeks.
During each week, the subject will wear one subcutaneous DexcomTM G4 or DexcomTM G4 Share
continuous glucose monitoring (CGM) system, one activity monitor- ActiGraph wGT3X-BT or
ActiGraph GT9X, one insulin pump (subject's own pump) and one Samsung Galaxy S4 phone loaded
with two applications- meal memory and moves. The CGM system will provide sensed glucose data
every 5 minutes. The CGM data will be blinded to the patient to prevent any abrupt changes in
behavior. The accuracy of the sensed data will be obtained by reference measurements of
capillary blood glucose. The activity monitor will be secured on the dominant wrist and uses
an accelerometer to collect movement data at a high frequency (80Hz). The activity monitor
measures both motion and ambient light, this data would be used to determine the various
sleep quality measures. The subject's insulin dosage information from the pump will be
downloaded for data analysis purposes. The subject's daily meal intake (photographic log and
note diary) and daily movement pattern information will be downloaded from the phone. During
the 4 exercise intervention visits, subject's heart rate, accelerometry information from the
torso and oxygen consumption measured breath by breath may be collected for data analysis
purposes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03482154 -
Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
|
||
Completed |
NCT03667053 -
Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children
|
Phase 3 | |
Active, not recruiting |
NCT03422471 -
Hypoglycemia and Autonomic Nervous System Function- B2
|
N/A | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05597605 -
The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects
|
N/A | |
Not yet recruiting |
NCT05990933 -
Role of Adrenaline in in the Inflammatory Response in Diabetes
|
N/A | |
Withdrawn |
NCT03736083 -
Introducing CGM at Type 1 Diabetes Diagnosis
|
N/A | |
Completed |
NCT02966275 -
Post Bariatric Closed Loop Glucagon Trial
|
N/A | |
Not yet recruiting |
NCT02909881 -
Dose Response Oxidation of a Sweet-corn Derived Sugar (PhytoSpherix) During Exercise in Endurance Trained Athletes
|
N/A | |
Withdrawn |
NCT02518022 -
How to be Safe With Alcoholic Drinks in Diabetes
|
N/A | |
Completed |
NCT02213003 -
Allogeneic Islet Cells Transplanted Onto the Omentum
|
Phase 1/Phase 2 | |
Completed |
NCT01176656 -
Hypoglycemia: Physician and Patient Perspectives
|
N/A | |
Completed |
NCT01147276 -
Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes
|
Phase 4 | |
Completed |
NCT00998374 -
Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge
|
N/A | |
Terminated |
NCT01225159 -
Tight Glycaemic Control During Cardiac Surgery
|
N/A | |
Completed |
NCT00373854 -
Study of How Low Blood Sugar Affects the Way Blood Vessels Work
|
N/A | |
Completed |
NCT00285233 -
Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes
|
Phase 1/Phase 2 | |
Recruiting |
NCT05916131 -
Pilot Feasibility Study for HypoPals, a Mobile Health Program for Improving Hypoglycemia Management.
|
N/A | |
Terminated |
NCT04026750 -
Insulin Tolerance Test Study in Patients With Type 1 Diabetes
|
Phase 1 | |
Completed |
NCT05133765 -
The SMART B Exercise Study :''The SMART Study''
|
N/A |